scholarly journals Roles of Aluminum Hydroxide and Monophosphoryl Lipid A Adjuvants in Overcoming CD4+ T Cell Deficiency To Induce Isotype-Switched IgG Antibody Responses and Protection by T-Dependent Influenza Vaccine

2016 ◽  
Vol 198 (1) ◽  
pp. 279-291 ◽  
Author(s):  
Eun-Ju Ko ◽  
Young-Tae Lee ◽  
Ki-Hye Kim ◽  
Youri Lee ◽  
Yu-Jin Jung ◽  
...  
Vaccines ◽  
2021 ◽  
Vol 9 (2) ◽  
pp. 131
Author(s):  
Christoph M. Janitzek ◽  
Philip H. R. Carlsen ◽  
Susan Thrane ◽  
Vijansh M. Khanna ◽  
Virginie Jakob ◽  
...  

Capsid-like particle (CLP) displays can be used to enhance the immunogenicity of vaccine antigens, but a better understanding of how CLP vaccines are best formulated and delivered is needed. This study compared the humoral immune responses in mice elicited against two different vaccine antigens (a bacterial protein and a viral peptide) delivered on an AP205 CLP platform using six different adjuvant formulations. In comparison to antibody responses obtained after immunization with the unadjuvanted CLP vaccine, three of the adjuvant systems (neutral liposomes/monophosphoryl lipid A/quillaja saponaria 21, squalene-in-water emulsion, and monophosphoryl lipid A) caused significantly increased antibody levels, whereas formulation with the three other adjuvants (aluminum hydroxide, cationic liposomes, and cationic microparticles) resulted in similar or even decreased antibody responses. When delivering the soluble bacterial protein in a squalene-in-water emulsion, 4-log lower IgG levels were obtained compared to when the protein was delivered on CLPs without the adjuvant. The AP205 CLP platform promoted induction of both IgG1 and IgG2 subclasses, which could be skewed towards a higher production of IgG1 (aluminum hydroxide). Compared to other routes, intramuscular administration elicited the highest IgG levels. These results indicate that the effect of the external adjuvant does not always synergize with the adjuvant effect of the CLP display, which underscores the need for empirical testing of different extrinsic adjuvants.


1995 ◽  
Vol 63 (1) ◽  
pp. 168-174 ◽  
Author(s):  
K R Myers ◽  
P Beining ◽  
M Betts ◽  
H Snippe ◽  
J Inman ◽  
...  

2018 ◽  
Vol 2018 ◽  
pp. 1-8 ◽  
Author(s):  
Suvi Heinimäki ◽  
Maria Malm ◽  
Timo Vesikari ◽  
Vesna Blazevic

Norovirus (NoV) is a main cause of acute gastroenteritis across all ages worldwide. NoV vaccine candidates currently in clinical trials are based on noninfectious highly immunogenic virus-like particles (VLPs) delivered intramuscularly (IM). Since NoV is an enteric pathogen, it is likely that mucosal immunity has a significant role in protection from infection in the intestine. Due to the fact that IM delivery of NoV VLPs does not generate mucosal immunity, we investigated whether NoV genotype GII.4 VLPs coadministered with aluminum hydroxide (Al(OH)3) or monophosphoryl lipid A (MPLA) would induce mucosal antibodies in mice. Systemic as well as mucosal IgG and IgA antibodies in serum and intestinal and nasal secretions were measured. As expected, strong serum IgG, IgG1, and IgG2a antibodies as well as a dose sparing effect were induced by both Al(OH)3and MPLA, but no mucosal IgA antibodies were detected. In contrast, IN immunization with GII.4 VLPs without an adjuvant induced systemic as well as mucosal IgA antibody response. These results indicate that mucosal delivery of NoV VLPs is needed for induction of mucosal responses.


2011 ◽  
Vol 18 (10) ◽  
pp. 1702-1709 ◽  
Author(s):  
Tansi Khodai ◽  
Debbie Chappell ◽  
Clare Christy ◽  
Paul Cockle ◽  
Jim Eyles ◽  
...  

ABSTRACTDespite several attempts to develop an effective prophylactic vaccine for HSV-2, all have failed to show efficacy in the clinic. The most recent of these failures was the GlaxoSmithKline (GSK) subunit vaccine based on the glycoprotein gD with the adjuvant monophosphoryl lipid A (MPL). In a phase 3 clinical trial, this vaccine failed to protect from HSV-2 disease, even though good neutralizing antibody responses were elicited. We aimed to develop a superior, novel HSV-2 vaccine containing either gD or gB alone or in combination, together with the potent adjuvant CpG oligodeoxynucleotides (CPG). The immunogenic properties of these vaccines were compared in mice. We show that gB/CPG/alum elicited a neutralizing antibody response similar to that elicited by gD/CPG/alum vaccine but a significantly greater gamma interferon (IFN-γ) T cell response. Furthermore, the combined gB-gD/CPG/alum vaccine elicited significantly greater neutralizing antibody and T cell responses than gD/MPL/alum. The efficacies of these candidate vaccines were compared in the mouse and guinea pig disease models, including a novel male guinea pig genital disease model. These studies demonstrated that increased immune response did not correlate to improved protection. First, despite a lower IFN-γ T cell response, the gD/CPG/alum vaccine was more effective than gB/CPG/alum in mice. Furthermore, the gB-gD/CPG/alum vaccine was no more effective than gD/MPL/alum in mice or male guinea pigs. We conclude that difficulties in correlating immune responses to efficacy in animal models will act as a deterrent to researchers attempting to develop effective HSV vaccines.


2014 ◽  
Vol 192 (9) ◽  
pp. 4221-4232 ◽  
Author(s):  
Weiguo Cui ◽  
Nikhil S. Joshi ◽  
Ying Liu ◽  
Hailong Meng ◽  
Steven H. Kleinstein ◽  
...  

2014 ◽  
Vol 174 ◽  
pp. 51-62 ◽  
Author(s):  
Harshad P. Patil ◽  
Senthil Murugappan ◽  
Wouter ter Veer ◽  
Tjarko Meijerhof ◽  
Aalzen de Haan ◽  
...  

1988 ◽  
Vol 56 (5) ◽  
pp. 1076-1083 ◽  
Author(s):  
P J Baker ◽  
J R Hiernaux ◽  
M B Fauntleroy ◽  
B Prescott ◽  
J L Cantrell ◽  
...  

Apmis ◽  
2019 ◽  
Vol 127 (3) ◽  
pp. 150-157 ◽  
Author(s):  
Nastaran Taleghani ◽  
Ali Bozorg ◽  
Amin Azimi ◽  
Homa Zamani

Sign in / Sign up

Export Citation Format

Share Document